NLRX1

AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases

Retrieved on: 
Monday, March 25, 2024
AbbVie, Ulcerative colitis, Patient, Inflammation, ABBV, Acquisition, IBD, MOA, Therapy, NLRX1, Calendar, Pharmaceutical industry

NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.

Key Points: 
  • NORTH CHICAGO, Ill. and NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- AbbVie Inc. (NYSE: ABBV) (“AbbVie”) and Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos”) today announced a definitive agreement under which AbbVie will acquire Landos, a clinical stage biopharmaceutical company focused on the development of novel, oral therapeutics for patients with autoimmune diseases.
  • Landos’ lead investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair.
  • “NX-13 and its bimodal MOA have the potential to provide a novel approach to the treatment of ulcerative colitis and Crohn’s disease.
  • The proposed transaction is expected to close in the second calendar quarter of 2024, subject to customary closing conditions, including approval by Landos’ stockholders.

Landos Biopharma Provides Business Update and Reports Fourth Quarter and Full Year 2023 Results

Retrieved on: 
Thursday, March 21, 2024
Research, Ulcerative colitis, ECCO, LTE, ACG, Patient, UC, Journal, Biomarker, NEXUS, Wind, Insurance, Abstract, American College, Clinical trial, Safety, Pharmacokinetics, Poster, NLRX1, European, PLXDC2, Pharmaceutical industry

NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or “the Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and reported financial results for the fourth quarter and the full year ended December 31, 2023.

Key Points: 
  • NEW YORK, March 21, 2024 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or “the Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and reported financial results for the fourth quarter and the full year ended December 31, 2023.
  • Top-line results are planned for the fourth quarter of 2024.
  • Research and development expenses were $3.1 million for the fourth quarter of 2023, compared to $3.4 million for the fourth quarter of 2022.
  • General and administrative expenses were $3.5 million for the fourth quarter of 2023, compared to $3.1 million for the fourth quarter of 2022.

NIMML Institute’s TITAN-X A.I.-Powered Precision Medicine Platform Validated through AbbVie’s Acquisition of Landos Biopharma and Lead Clinical Candidate NX-13

Retrieved on: 
Monday, March 25, 2024
Health, Health Technology, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, AbbVie, Ulcerative colitis, Growth, I&I, Cell, ACG, Patient, ABBV, UC, Journal, Biomarker, NIMML, Acquisition, LANCL2, IPO, SLE, Personalized medicine, Volunteering, A.I, IBD, Medicine, Rheumatoid arthritis, Epithelium, DRS, Invention, Therapy, NLRX1, Work, Pharmaceutical industry

and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.

Key Points: 
  • and computational modeling capabilities were instrumental for the characterization of NLRX1 as a therapeutic target for autoimmune diseases and the development of NX-13.
  • “Importantly, AbbVie is one of the world’s largest biopharma companies with an incredibly successful I&I franchise that it has built over the last two decades.
  • In addition to Landos Biopharma, Dr. Bassaganya-Riera founded NImmune Biopharma (“NImmune”) with the purpose to advance the clinical development of the LANCL2 portfolio of immunoregulatory precision medicines.
  • Both omilancor and NIM-1324 are guided by precision biomarkers discovered and developed by NIMML’s TITAN-X A.I.-powered Precision Medicine platform.

Landos Biopharma to Present New Data on Immunometabolism at the 19th Annual Congress of the European Crohn’s and Colitis Organisation

Retrieved on: 
Monday, January 8, 2024
Human, Treatment, Chronic pain, Homeostasis, PLXDC2, Ulcer, Disease, UC, Doctor of Philosophy, ECCO, Pharmacokinetics, NLRX1, Abstract, UZ Leuven, Library, Congress, European, Effect, Inflammatory Bowel Diseases, Inflammation, Patient, Translation, Immunometabolism, Safety, Landos, NEXUS, Pharmaceutical industry

The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69.

Key Points: 
  • The abstracts highlight new and additional data on immunometabolism modulation by activating NLRX1 and PLXDC2 with novel agonists such as NX-13 and LABP-69.
  • The ECCO congress will take place February 21-24, 2024 in Stockholm, Sweden.
  • We are excited to present data from multiple studies including the impact of NX-13 on eosinophil infiltration and visceral hypersensitivity, as well as confirming its relevancy in multiple models and species.
  • Additionally, we are pleased to share new preclinical insights into the potential role of PLXDC2 in ulcerative colitis,“ said Fabio Cataldi, M.D., Executive Vice-President & Chief Medical Officer at Landos.

Landos Biopharma Publishes Results of NX-13 Phase 1b Study in Ulcerative Colitis in Journal of Crohn’s and Colitis

Retrieved on: 
Tuesday, November 21, 2023
Pharmacokinetics, NLRX1, Patient, Landos, NEXUS, Journal, Ulcerative colitis, Pharmaceutical industry

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced a peer-reviewed publication describing the safety, tolerability, pharmacokinetic and clinical efficacy results for the NX-13 Phase 1b trial in patients with ulcerative colitis (UC) in the Journal of Crohn’s and Colitis.

Key Points: 
  • “We are delighted to have our Phase 1b results of NX-13 in UC published in the Journal of Crohn’s and Colitis,” said Dr. Fabio Cataldi, Executive Vice-President & Chief Medical Officer at Landos.
  • NX-13 was found to be well tolerated in all patients studied.
  • No deaths or severe adverse events were reported and all adverse events were mild to moderate.
  • “The early signs of efficacy, along with a favorable safety profile, highlighted in this publication are encouraging.

Landos Biopharma Provides Company Update and Reports Third Quarter 2023 Results

Retrieved on: 
Thursday, November 9, 2023
Research, United European Gastroenterology, American College, NLRX1, UC, D&O, Biomarker, NEXUS, ACG, Wind, American College of Gastroenterology, D, Poster, Ulcerative colitis, Inflammatory bowel disease, LTE, UZ Leuven, KU Leuven, Pharmacokinetics, Clinical trial, Epithelium, Ulcer, Safety, Patient, Gene expression, Pharmaceutical industry

NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the quarter ended September 30, 2023.

Key Points: 
  • NEW YORK, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today provided a business update and announced financial results for the quarter ended September 30, 2023.
  • NEXUS Phase 2 proof-of-concept clinical trial:
    The NEXUS trial of NX-13 remains on track as the Company continues to recruit, screen and randomize patients for the trial.
  • Research and development expenses were $3.1 million for the third quarter of 2023, compared to $4.9 million for the third quarter of 2022.
  • General and administrative expenses were $2.1 million for the third quarter of 2023, compared to $3.0 million for the third quarter of 2022.

Landos Biopharma to Present at the American College of Gastroenterology 2023 Annual Scientific Meeting

Retrieved on: 
Monday, October 23, 2023
American College, NLRX1, Biomarker, UC, NEXUS, ACG, American College of Gastroenterology, Patient, Pharmaceutical industry, Book, Ulcerative colitis

NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will present additional findings from its Phase 1b study of NX-13 for the treatment of ulcerative colitis (UC), including detailed results on the rapid symptomatic relief and improvement in multiple clinical biomarkers observed in the study, at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting, being held October 20-25 in Vancouver, Canada.

Key Points: 
  • NEW YORK, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced that it will present additional findings from its Phase 1b study of NX-13 for the treatment of ulcerative colitis (UC), including detailed results on the rapid symptomatic relief and improvement in multiple clinical biomarkers observed in the study, at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting, being held October 20-25 in Vancouver, Canada.
  • “We are excited for the opportunity to present at a premier gastroenterology event like ACG and share additional findings from our Phase 1b study of NX-13 in patients with UC,” said Gregory Oakes, President and CEO of Landos.
  • “The presentations cover the rapid symptomatic relief and improvements in multiple biomarkers, correlating with early endoscopic response of NX-13 in patients with moderate-to-severe UC.
  • The data highlight the potential of NX-13 to transform the standard of care in moderate-to-severe UC with an oral, once-daily treatment, and further our confidence in the ongoing NEXUS proof-of-concept trial.”
    The Company continues to actively recruit, screen and randomize patients for the NEXUS trial, with topline results expected by the fourth quarter of 2024.

Landos Biopharma to Present New Data on NX-13 from Phase 1b Trial in Ulcerative Colitis at United European Gastroenterology (UEG) Week 2023 Congress

Retrieved on: 
Tuesday, September 19, 2023
IBD, Icahn School of Medicine at Mount Sinai, UEG, Biomarker, Guanine nucleotide exchange factor, NEXUS, Clinical trial, UC, Patient, NLRX1, UZ Leuven, Congress, Pharmaceutical industry, Book, Music, Ulcerative colitis, KU Leuven, Medicine

NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced presentation of new data on the rapid symptomatic relief and improvement in multiple clinical biomarkers observed with NX-13 in its Phase 1b study in UC at the upcoming UEG Week 2023 congress in Copenhagen, Denmark and virtually from October 13 to October 17, 2023.

Key Points: 
  • NEXUS Phase 2 Clinical Trial is Ongoing; Top-line Readout Expected in Q4 2024
    NEW YORK, Sept. 19, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced presentation of new data on the rapid symptomatic relief and improvement in multiple clinical biomarkers observed with NX-13 in its Phase 1b study in UC at the upcoming UEG Week 2023 congress in Copenhagen, Denmark and virtually from October 13 to October 17, 2023.
  • “We are excited to have the innovative work of the Landos team and our collaborators selected for two oral presentations and one poster presentation at UEG Week - one of the top gastroenterology congresses in the world,” said Gregory Oakes, President and CEO of Landos.
  • “We believe this data continues to strengthen the scientific and clinical foundation for NX-13 and its novel, bimodal mechanism of action targeting NLRX1.
  • First, by showing rapid symptomatic relief to patients as early as two weeks; and second, by demonstrating improvement in multiple biomarkers that correlate with early endoscopic response.

Landos Biopharma Announces Strategic Research Collaboration with KU Leuven and University Hospitals Leuven to Further Characterize the Effects of NX-13 on Epithelial Cells

Retrieved on: 
Thursday, September 14, 2023
IBD, Epithelium, Clinical trial, Landos, Research, Gene expression, Inflammation, Ulcerative colitis, NEXUS, Patient, UZ Leuven, Inflammatory bowel disease, Environment, KU Leuven, NLRX1, Pharmaceutical industry, UC

The NEXUS Phase 2 proof-of-concept clinical trial of NX-13 in patients with moderate-to-severe ulcerative colitis (UC) was initiated during the second quarter of 2023.

Key Points: 
  • The NEXUS Phase 2 proof-of-concept clinical trial of NX-13 in patients with moderate-to-severe ulcerative colitis (UC) was initiated during the second quarter of 2023.
  • Recruitment, screening and randomization of patients continues, with top-line results on track for the fourth quarter of 2024.
  • The results are expected to provide further insight into the impact of NX-13 on gene expression and regulation, and cytokine responses.
  • Landos expects to present results from this research collaboration at appropriate medical conferences in 2024.

Landos Biopharma Announces Transfer of LANCL Portfolio, including Omilancor, LABP-104 and LABP-111 to Landos’ Founder

Retrieved on: 
Tuesday, February 28, 2023
Clinical trial, Endoscopy, Krause, Alzheimer's disease, Diabetic nephropathy, Retirement, Acquisition, UC, Cooley LLP, Patient, Chronic obstructive pulmonary disease, Ulcerative colitis, Multiple sclerosis, NLRX1, Rheumatoid arthritis, Disease, Pharmaceutical industry, Security (finance), Risk management, Landos, Asthma

NEW YORK, Feb. 28, 2023 (GLOBE NEWSWIRE) -- Landos Biopharma, Inc. (NASDAQ: LABP) (“Landos” or the “Company”), a clinical-stage biopharmaceutical company developing novel, oral medicines for patients with autoimmune diseases, today announced the transfer of its LANCL portfolio, including Omilancor, LABP-104 and LABP-111 to Dr. Josep Bassaganya-Riera, Ph.D., the founder of Landos who previously served as its Chairman, President and CEO, and certain affiliated individuals and entities.

Key Points: 
  • The parties have also agreed to a mutual, general release of liabilities and claims.
  • The transaction follows a comprehensive strategic review of the Landos portfolio.
  • Consistent with Landos’ strategic update in January 2023, this transaction streamlines the Company’s portfolio, enhancing its focus and resources on advancing NX-13.
  • Landos previously announced top-line results from its NX-13 Phase 1b trial in UC patients in August 2022.